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Abstract: Accurate diagnosis and staging are essential for an optimal management of cancer patients. Positron emision 
tomography with 2-deoxy-2-ﬂ  uorine-18-ﬂ  uoro-D-glucose (
18FDG-PET) and, more recently, 
18FDG-PET/computed tomog-
raphy (
18FDG-PET/CT) have emerged as powerful imaging tools in oncology, because of the valuable functional informa-
tion they provide. The combined acquisition of PET and CT has synergistic advantages over its isolated constituents and 
minimizes their limitations. It decreases examination times by 25%–40%, leads to a higher patient throughput and uniﬁ  cates 
two imaging procedures in a single session. There is evidence that 
18FDG-PET/CT is a more accurate test than either of its 
components for the evaluation of various tumors. It is a particularly valuable tool for detection of recurrence, especially in 
asymptomatic patients with rising tumor markers and those with negative or equivocal ﬁ  ndings on conventional imaging 
tests. Yet, there are some limitations and areas of uncertainty, mainly regarding the lack of speciﬁ  city of the 
18FDG uptake 
and the variable 
18FDG avidity of some cancers. This article reviews the advantages, limitations and main applications of 
18FDG-PET/CT in oncology, with especial emphasis on lung cancer, colorectal cancer, lymphomas, melanoma and head 
and neck cancers.
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Introduction
Cancer is one of the leading causes of death worldwide. Accurate diagnosis, staging and restaging are 
essential for an adequate therapeutic management of these patients. Conventional imaging techniques, 
such as computed tomography (CT) and magnetic resonance rely on anatomic alterations and abnormal 
contrast enhancement, with limitations to detect inﬁ  ltration in normal-sized structures and characteriza-
tion of residual lesions. Positron emision tomography (PET) with 2-deoxy-2-ﬂ  uorine-18-ﬂ  uoro-D-
glucose (
18FDG), an analogue of glucose, provides valuable functional information based on the increased 
glucose uptake and glycolysis of cancer cells. Therefore, PET has the ability to depict metabolic abnor-
malities before morphologic alterations occur. The main drawback of PET is the limited spatial resolu-
tion which impedes precise localization of foci of 
18FDG uptake and hinders identiﬁ  cation of lesions 
adjacent to organs with physiological 
18FDG uptake (urinary tract, bowel) (Shreve et al. 1999). In addi-
tion, 
18FDG is physiologically taken up by various organs and also by sites of inﬂ  ammation. The hybrid 
PET/CT modality acquires PET and CT data in the same imaging session and allows accurate anatomic 
localization of the lesions detected on the 
18FDG-PET scan. Since its introduction integrated PET/CT 
has rapidly gained clinical acceptance and, in the last decade it has become an important imaging tool 
in clinical oncology.
In this article, we review the advantages, limitations, clinical utility, and main applications of com-
bined 
18FDG-PET/CT in oncology.
General Aspects of Combined PET/CT
Advantages of combined 
18FDG-PET/CT
There are several advantages of combined PET/CT over its isolated constituents, that translate into 
highly synergistic beneﬁ  ts in the management of a variety of cancers.182
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Technical advantages
From a technical point of view, the use of CT data 
photon attenuation correction instead of data from 
an external radioactive transmission source results 
in a much faster PET image acquisition, decreasing 
examination times by 25%–40% relative to stand-
alone PET (Hany et al. 2002; von Schulthess et al. 
2006). Straightforward consequences are a higher 
patient throughput and a more efﬁ  cient use of the 
fast-decaying PET radiopharmaceutical (Hany 
et al. 2002). In addition, owing to the high photon 
ﬂ  ux used for CT attenuation correction the noise 
is reduced and the image quality of the PET scan 
is improved (Carney et al. 2003).
Clinical advantages
For the patient, the decreased scan time and uniﬁ  -
cation of the two imaging procedures in a single 
session, performing preparation such as fasting 
only once, lead to a greater patient comfort and 
convenience.
The most remarkable clinical advantage of the 
integrated PET/CT is the accurate co-registration 
of metabolic and anatomic data, providing 
improved lesion localization and characterization, 
which results in a signiﬁ  cant reduction of false-
positive and false-negative ﬁ  ndings, and increased 
diagnostic and staging accuracy of numerous can-
cers as compared with either modality (Charron 
et al. 2000; Hany et al. 2002; Israel et al. 2002; 
Antoch et al. 2003; Bar-Shalom et al. 2003, Bris-
tow et al. 2003; Czernik et al. 2003). In general, 
the CT component adds mainly speciﬁ  city, whereas 
PET adds mostly sensitivity. Thus, the combined 
PET/CT is a more sensitive and speciﬁ  c test than 
either of its constituents obtained separately (von 
Schulthess et al. 2006). Other beneﬁ  ts of PET/CT 
include identiﬁ  cation of small lesions that might 
be overlooked on either PET or CT alone, normal-
sized malignant nodes (Fig. 1), conﬁ  dent charac-
terization of suspicious or equivocal ﬁ  ndings on 
other imaging techniques, and biopsy guidance. In 
addition, the gathered functional and anatomic data 
are integrated by the interpreting physicians in a 
single report, with a diagnostic impression formu-
lated from the combination of both techniques, that 
facilitates the transfer of diagnostic information to 
the referring physicians. It must be noted that the 
quality of the CT component is variable depending 
on the institution and clinical indication for PET/
CT. Hence, the PET/CT report should specify 
whether the CT scan was performed with a very 
low current (such as 10 mAs) or low current (40–80 
mAs) for attenuation correction and anatomic 
localization only, or with full dose for diagnostic 
purposes, and the use of contrast agents, to decide 
the need for further morphologic imaging. In addi-
tion, because of the synergistic beneﬁ  ts of the 
combined acquisition of both modalities, the 
administration of intravenous contrast material can 
be eliminated for certain indications (e.g. monitor-
ing response to therapy) (Wong et al. 2007). These 
beneﬁ  tial aspects of PET/CT potentially improve 
the management of cancer patients.
Limitations and pitfalls of combined 
18FDG-PET/CT
There are potential pitfalls of PET/CT related to 
technical factors. Patient motion during imaging 
acquisition may produce misregistration on the 
fused images and cause confusion or mistakes 
regarding the correct localization of the 
18FDG 
uptake (Kapoor et al. 2004). Although patient 
movement and breathing motion can be minimized 
by placing the patient in a comfortable position 
and acquiring CT in normal expiration, some arti-
facts caused by respiratory, cardiac or bowel 
motion are unavoidable. These mismatchs are 
readily identiﬁ  ed by carefully reviewing both sets 
of images, and usually do not create diagnostic 
dilemmas. A drawback of acquiring the CT in 
expiratoty phase instead of instead of full inspira-
tion is that the chest images show, compared with 
diagnostic thoracic CT scans, lower lung volumes 
and more dependent atelectasis and ground-glass 
opacities that potentially obscure small nodules. 
Even though, the chest images of PET/CT are usu-
ally of an adequate quality for most of the onco-
logic indications (Wong et al. 2007). In selected 
cases an additional inspiratory thoracic CT can be 
performed after the acquisition of PET/CT in expi-
ration. Attenuation correction artifacts that may 
occur with high-density elements such as metallic 
devices are easily recognized on uncorrected PET 
images, which are always available.
Limitations of 
18FDG-PET/CT in the evaluation 
of cancer have been documented as well. 
18FDG 
is not a cancer-speciﬁ  c tracer and accumulates in 
areas of increased metabolism such as several 
normal organs (brain, salivary glands, vocal cords, 
myocardium, urinary tract), and brown fat. 
Although the better anatomic localization and 183
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morphologic information of 
18FDG-PET/CT 
improves the diagnostic accuracy compared to PET 
standalone, in occasions, tumor detection may be 
impaired in these structures, even on 
18FDG-PET/
CT. In this regard, relatively small brain metastases 
can be missed on 
18FDG-PET/CT owing to the high 
background activity. Hence, symptomatic patients 
with negative scans or those at high risk for brain 
metastases will require further imaging with MRI 
or contrast-enhanced CT. 
18FDG is also taken up 
by activated leukocytes and macrophages, resulting 
in enhanced uptake in sites of active inﬂ  ammation 
and tissue repair (infection, sarcoidosis, vasculitis, 
post-radiotherapy and post-surgery changes, etc) 
(Fig. 2). The ﬁ  ndings on the CT component may 
facilitate the interpretation of 
18FDG-avid lesions, 
e.g. the morphologic changes secondary to a bone 
fracture. However, exclusion of malignancy may 
be impossible based on 
18FDG-PET/CT images 
only, and correlation with clinical data is essential 
to the correct interpretation of scans. In addition, 
a variety of benign tumors in the head and neck 
and colonic adenomas may exhibit an increased 
uptake.
On the other hand, there are limitations related 
to the variability in 
18FDG uptake of several types 
of cancers. Well-differentiated, hypo-cellular and 
mucin-producing tumors (and their metastases), 
such as bronchioalveolar carcinoma, hepatocel-
lular carcinoma and intraductal papillary mucinous 
tumor exhibit low 
18FDG uptake (Berger et al. 
2000) (Fig. 3). Yet, this limitation of 
18FDG-PET/
CT may be valuable in certain cases, as the degree 
of 
18FDG uptake may be correlated with the 
Figure 1. 
18FDG PET/CT study of a 60 year-old man with NSCLC. There is a large mass in right upper lobe that exhibits peripheral hyper-
metabolic activity consistent with tumor viability and central photopenia suggesting necrosis of the tumor. A small lymph node in the right 
lower paratracheal area with increased 
18FDG uptake is observed (arrow). Histological examination demonstrated metastatic inﬁ  ltration.184
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Figure 2A y 2B. False-positive FDG-uptake in viral infection. Forty-seven year-old woman referred for staging of T-cell non-Hodgkin’s lymphoma. 
18FDG PET (B, D) 
18FDG PET/CT fusion (C) scans shows abnormal foci of 
18FDG uptake in the left axilla (2A) (arrow) and the skin overlying 
the left breast (2B) (arrow). The ﬁ  ndings were misinterpreted as cutaneous and nodal lymphomatous inﬁ  ltration. Skin and axillary node biopsies 
demonstrated herpes virus infection and benign reactive follicle hyperplasia respectively. There was no evidence for malignancy.185
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biological aggresiveness with a prognostic 
signiﬁ  cance, and help to select therapies (Yang 
et al. 2005).
Clinical utility
18FDG PET/CT has proven effective for diagnosis 
and staging of various cancers (Beyer et al. 2000), 
especially non-small-cell lung carcinoma (NSCLC), 
lymphoma, recurrent colorectal carcinoma, mela-
noma and sarcomas. Recently, especial attention 
has been focused on restaging and monitoring 
tumor response, where this technique is probably 
most useful (Oriuchi et al. 2006). 
18FDG PET/CT 
is a valuable tool for detection of recurrence, par-
ticularly in asymptomatic patients with rising 
levels of tumor markers and also in patients with 
negative or equivocal ﬁ  ndings on conventional 
imaging tests. In patients with residual masses after 
therapy completion or with post-surgical or post-
radiation anatomic distortion, 
18FDG PET/CT 
allows accurate differentiation between viable 
tumor and necrosis or scar. With its precise ana-
tomic correlation, it may be used to direct diag-
nostic biopsy to the speciﬁ  c site of 
18FDG uptake 
to obtain tissue conﬁ  rmation of recurrence. Thus, 
relapses can be early detected and treated, while 
tumoral burden is still low. Conversely, exclusion 
of recurrence in areas of post-therapy morphologic 
abnormalities avoids unnecessary diagnostic pro-
cedures and treatments. However, studies per-
formed within 2–3 months of radiation or 1–2 
months of surgery may yield false-positive ﬁ  nd-
ings, as post-therapeutic inflammation causes 
18FDG uptake (Hojgaard et al. 2007; Oriuchi et al. 
2006; Von Schulthess et al. 2006).
Because metabolic changes in a tumor precede 
size reduction, 
18FDG PET/CT is effective for 
assessment of response to therapy. Successful 
chemotherapy decreases cellular glucose transport 
and glycolysis and, hence, tumor uptake of 
18FDG. 
It has been reported that a decrease in 
18FDG 
uptake may be observed as early as 1–2 weeks 
after the ﬁ  rst cycle of effective chemotherapy 
Figure 3. Recurrence of cholangiocarcinoma in a patient who had undergone surgical tumor resection. The CT scan (A) shows a mass at 
the site of previous surgery in contact with the pancreatic head (arrow). The lesions shows minimal 
18FDG uptake on 
18FDG PET (B, D) and 
18FDG PET/CT fusion (C) images (arrow).186
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(Brun et al. 2002; Kostakoglu et al. 2002; Weber 
et al. 2003). In this way, 
18FDG PET/CT enables 
early identiﬁ  cation of non-responders and a change 
in therapy.
Available information in the literature on the 
impact of 
18FDG PET/CT on radiotherapy treat-
ment planning is limited (Van Baardwijk et al. 
2006; Greco et al. 2007). However, current data 
suggest an improvement in target volume delinea-
tion. In this way, 
18FDG PET/CT may modify 
radiotherapy ﬁ  elds to reduce radiation dose to 
normal tissues and allow selective dose escalation 
to hypermetabolic areas within the tumoral mass. 
The advantages of 
18FDG PET/CT seem to be more 
relevant in lung cancer, enabling differentiation 
between tumor and atelectasis and detection of 
unsuspected metastatic lymph nodes, and in head 
and neck carcinomas, where a better delineation 
of involved sites may reduce sequelae of radiation. 
Further research is needed to determine the exact 
role of 
18FDG PET/CT in radiotherapy treatment 
planning, however.
Radiation dose
There is some concern regarding the higher 
radiation exposure of 
18FDG PET/CT in comparison 
to PET standalone, especially in oncologic patients 
who will undergo repetitive scans for tumor follow-
up. Tipically, a PET scan with 370 MBq (10mCi) 
of 
18FDG delivers a dose of approximately 11 mSv 
to a patient, predominantly owing to the positrons 
emitted from isotopes. This dose is comparable to 
that of a diagnostic CT, ranging from 10 to 20 mSv. 
With the use of a CT scan for attenuation correction 
and anatomic coregistration the patient receives an 
additional dose that will vary depending on the 
quality of the CT scan and the protocol used: low-
dose unenhanced-CT (LD-CT), full-dose contrast-
enhanced-CT (FD-CT). A LD-CT with 40 mAs 
adds approximately 2 to 8 mSv, resulting in a ﬁ  nal 
dose of 13–20 mSv for an integrated LD-
18FDG 
PET/CT study, which is similar to a diagnostic 
contrast-enhanced CT. A LD-
18FDG PET/CT 
performed with 40–80 mAs yields an adequate 
image quality and may sufﬁ  ce for many, though 
not for all, 
18FDG PET/CT oncologic applications 
(see below) (Brix et al. 2005; Kneifel et al. 2003). 
Nevertheless, the risk-beneﬁ  t ratio has to be taken 
into account in the individual patient, as correct 
diagnosis, staging and restaging are essential for 
an optimised and individualised therapy.
Major Indications of 
18FDG PET/CT 
in Oncology
Solitary pulmonary nodule (SPN)
18FDG PET/CT helps characterize SPN, as most 
of malignant nodules show increased glucose 
metabolism (Fig. 4). The diagnostic accuracy of 
18FDG PET depends on the size of the nodule and 
its avidity for 
18FDG, and false-negative studies 
have been reported in nodules smaller than 1 cm, 
well-differentiated adenocarcinoma, bronchial-
veolar cell carcinoma, and carcinoid (Higashi et al. 
1998; Gould et al. 2001). False-positive ﬁ  ndings 
include infectious and inﬂ  ammatory processes such 
as tuberculosis (Fig. 5), fungal infections, and 
sarcoidosis. It has been reported that 
18FDG PET/
CT can reliably characterize SPN   7 mm (sen-
sitivity 97%, speciﬁ  city 85%, overall accuracy 
93%) (Kim et al. 2007), providing valuable infor-
mation to guide patient management, especially 
useful where biopsy is risky, in elderly patients, or 
when there is a low risk for malignancy. This, SNPs 
with increased 
18FDG uptake are likely malignant 
and should undergo further invasive resection or 
biopsy. However, nodules PET negative still need 
to be followed (usually by CT) because of the pos-
sibility of false-negative PET ﬁ  nding (Christensen 
et al. 2006).
Non-small cell lung cancer (NSCLC)
18FDG PET/CT has an important role in the initial 
staging, restaging, and in radiotherapy planning. 
Advantages of combined 
18FDG PET/CT over its 
isolated components in NSCLC evaluation include: 
better lesion identiﬁ  cation and localization, higher 
detection rate of lesions with low 
18FDG afﬁ  nity, 
and depiction of tumoral inﬁ  ltration in small lymph 
nodes.
18FDG PET/CT has been reported to be the most 
accurate imaging technique in staging NSCLC, 
with accuracies for tumor (T), nodal (N) and metas-
tases (M) staging of 70%–97%, 78%–93% and 
83%–96% respectively (Lardinois et al. 2003; 
Sachelarie et al. 2005). The most important ben-
eﬁ  t of the integrated modality relates to T staging, 
where 
18FDG PET/CT is clearly superior to either 
of its constituents, mainly due to the precise ana-
tomic localization of the 
18FDG uptake (Lardinois 
et al. 2003; Halpern et al. 2005; Shim et al. 2005). 
Thus, CT improves depiction of focal chest wall 187
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Figure 4. 70 year-old man referred for evaluation of a pulmonary solitary nodule evaluation. Axial CT scan shows a 2.8 cm pulmonary lung 
in the right upper lobe with spiculated margins and emphysema. 
18FDG PET and 
18FDG PET/CT fusion images reveal increased 
18FDG 
uptake in the nodule. The lesion corresponded to a squamous-cell carcinoma.
Figure 5. 68 year-old woman that presented with a pulmonary node at chest radiograph. A nodule with pleura tail and increased 
18FDG 
uptake is observed in the right upper lobe at 
18FDG PET/CT scan. The histologic study demonstrated tuberculoma.188
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and mediastinum inﬁ  ltration and vascular invasion 
(Lardinois et al. 2003), whereas PET is useful in 
differentiating tumor from post-obstructive atelec-
tasis (Fig. 6) and characterizing pleural effusions 
as malignant (Schaffer et al. 2004; Lavrenov et al. 
2005; Devaraj et al. 2007). It should be stressed 
the need to perform a diagnostic CT with intrave-
nous iodinated contrast material in order to achieve 
a precise deﬁ  nition of tumor extension, distinguish 
contiguity of tumor and mediastinum from the 
direct invasion of the walls of mediastinal struc-
tures, and depict vascular invasion (Lardinois et al. 
2003; von Schulthess et al. 2006; Pfannenberg 
et al. 2007). This is of utmost importance for both, 
planning of 3D conformal radiotherapy and 
extended non-conventional surgery. Recently, 
Pfannenberg et al. found that contrast-enhanced 
PET/CT more accurately assessed the TNM stage 
in 8% of patients with advanced NSCLC compared 
with non-contrast PET/CT, and showed signiﬁ  cant 
additional ﬁ  ndings in 20%. They suggest that contrast-
enhanced PET/CT should be performed in all 
patients with NSCLC who are primarily considered 
for local therapy such as surgery, neoadjuvant 
radiochemotherapy or definitive radiotherapy 
(Pfannenberg et al. 2007). Although PET/CT also 
has a higher diagnostic accuracy than either CT or 
PET alone for N staging (Lardinois et al. 2003), 
the improvement with respect to PET alone is more 
modest. The beneﬁ  t lies in a higher speciﬁ  city of 
PET/CT attributed to the precise anatomic informa-
tion provided by the CT component. This is par-
ticularly useful for localization of lymph node 
metastases in patients with a mediastinal shift of 
Figure 6. 58 year-old man who underwent contrast-enhanced integrated 
18FDG PET/CT for staging of newly diagnosed squamous carcinoma. 
Axial contrast-enhanced CT (A), axial (B) and coronal (D) PET and fused enhanced 
18FDG PET/CT (C) images. Integrated enhanced 
18FDG 
PET/CT (C) depicts the left upper lobe central 
18FDG avid mass within the non-hypermetabolic collapsed lung parenchyma and allows dif-
ferentiation between tumor and surrounding post-obstructive atelectasis. Thanks to the contrast-enhanced CT component of 
18FDG PET/CT 
it is possible to delineate inﬁ  ltration of the mediastinum and left pulmonary artery, classifying the tumor as a T4 stage. A left pleural effusion 
without 
18FDG uptake is also noted. Accurate delineation of the tumor is important for radiation therapy planning.189
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with small solitary nodes that could be difﬁ  cult on 
PET alone (von Schulthess et al. 2006). 
18FDG 
PET and 
18FDG PET/CT have a high negative 
predictive value for nodal involvement, greater 
than 90% (Pieterman et al. 2000; Schrevens et al. 
2004, Pozo-Rodríguez et al. 2005). However, false-
negatives due to micrometastases (“minimal N2 
disease”) can occur in up to 8% of patients, 
although these patients have a better prognosis 
(Schrevens et al. 2004). The value of 
18FDG PET/
CT in nodal staging is limited by the low positive 
predictive value caused by inﬂ  ammatory changes 
in lymph nodes, especially in geographic areas with 
a high prevalence of granulomatous disease. For 
this reason, it is necessary to obtain histologic 
conﬁ  rmation of positive lymph nodes that would 
preclude surgery (De Langen et al. 2006). 
18FDG 
PET performs well at depicting extrathoracic 
metastases and detects unsuspected metastases in 
up to 28% of patients with NSCLC (Eschmann 
et al. 2002; Lardinois et al. 2003) (Fig. 7). The CT 
component provides exact localization of the PET 
ﬁ  ndings as well as complementary morphologic 
information that is especially useful in cases of 
doubtful adrenal lesions. In this regard, measure-
ment of the Hounsﬁ  eld Units of the lesion on the 
non-enhanced CT images (which are usually avail-
able) with the possible addition of a delayed 
enhanced CT at the end of the exploration may 
help characterize doubtful lesions, such as adenoma 
depicting 
18FDG uptake (Elaini et al. 2007; Metser 
et al. 2006; Pfannenberg et al. 2007).
On the other hand, it should be noted that 
18FDG PET/CT is not a sensitive technique for the 
detection of brain metastases because of the dif-
ﬁ  culty in depicting 
18FDG-avid lesions in the 
physiologically hypermetabolic brain parenchyma 
(Bruzzi et al. 2006; Devaraj et al. 2007). For this 
reason, further imaging with brain MRI may be 
needed.
18FDG PET/CT also has a signiﬁ  cant value in 
the assessment of suspected relapse, being par-
ticularly useful in cases with postherapy anatomic 
distortion (Keidar et al. 2004).
Figure 7. 58-year-old man who underwent 
18FDG PET/CT for initial staging of NSCLC. Coronal CT, PET and fused 
18FDG PET/CT images 
depicted a intraparenchymatous right renal lesion with intense 
18FDG uptake which were histologically proved to be metastatic disease (small 
arrows). The central upper left lobe pulmonary mass with lung atelectasis is also observed (large arrows).190
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Colorectal cancer
Although considered potentially useful in the 
diagnosis and initial staging of colorectal cancer, 
currently there is no evidence of the superiority of 
18FDG PET/CT over standard diagnostic work-up 
(Pelosi et al. 2007). However, 
18FDG PET/CT has 
proven extremely useful in the assessment of 
patients with suspected recurrence. Early detection 
of recurrent disease is essential to perform an 
optimal salvage treatment and improve survival. 
Evaluation with CT of these patients is limited by 
its inability to differentiate between post-surgical 
or post-radiation scar tissue and recurrent disease, 
and to detect tumoral inﬁ  ltration of normal-sized 
lymph nodes. This is particularly true for the 
evaluation of post-treatment presacral masses, 
which occur in an elevated proportion of patient 
and poses a clinical challenge (Fig. 8).
18FDG PET is very helpful in characterization 
of inconclusive lesions on morphologic imaging 
techniques, with reported diagnostic accuracies 
ranging from 74% to 95% as compared with 65% 
to 78% for CT (Schiepers et al. 1999; Huebner 
et al. 2000; Schaefer et al. 2007). 
18FDG PET is 
also useful to localize occult metastatic disease in 
patients with rising tumor marker levels and nega-
tive conventional imaging tests, and identify 
unsuspected metastases in up to 25% of patients 
(Pelosi et al. 2007). There are limitations to PET, 
however. The lack of anatomic landmarks probably 
accounts for its relatively low speciﬁ  city (76%) 
(Huebner et al. 2000), the false-positive interpreta-
tions of physiologic 
18FDG uptakes in pelvis with 
post-treatment anatomic distortion (Even-Sapir 
et al. 2004), rendering it unsuitable for guiding 
biopsy, surgery of radiation. In addition, lesions 
below its spatial resolution (6mm) and those with 
low 
18FDG uptake, such as mucinous adenocarci-
nomas can be missed on PET (Kamel et al. 
2004).
Figure 8. Local recurrence of colon cancer. Fifty-one year-old woman, status post-resection of sigmoid adenocarcinoma, referred for 
reevaluation. Axial CT (A) scan shows a nonspeciﬁ  c small soft-tissue mass at the site of previous surgery (arrow). Axial 
18FDG PET scan 
(B) reveals focal intense accumulation of 
18FDG in the pelvis that is difﬁ  cult to localize anantomically. Axial fused 
18FDG PET/CT (C) image 
clearly demonstrates that the increased 
18FDG uptake corresponds to the soft-tissue mass. Recurrent adenocarcinoma was histologically 
conﬁ  rmed. Note unspeciﬁ  c 
18FDG uptake in the morphologically normal right colon (physiologic variant).191
PET/CT in oncology
Clinical Medicine: Oncology 2008:2 
Many of these drawbacks are overcome with 
18FDG PET/CT. Several studies show the superior-
ity of the combined modality in the detection of 
local recurrence of colorectal cancer, with sensi-
tivities, speciﬁ  cities and diagnostic accuracies of 
96%–100%, 96%–97% and 93%–96% respectively 
(Even-Sapir et al. 2004; Selzner et al. 2004; 
Schöder H et al. 2004; Votrubova et al. 2006; 
Pelosi et al. 2007). In a prospective study by 
Selzner et al. (Selzner et al. 2004) evaluating 
contrast-enhanced CT and unenhanced 
18FDG 
PET/CT in metastatic colorectal cancer, both 
modalities yielded comparable sensitivities for the 
detection of liver metastases (95% and 91% respec-
tively), but 
18FDG PET/CT was superior for the 
diagnosis of intrahepatic recurrence after hepatec-
tomy (50% versus 100%, p = 0.04), and extrahe-
patic disease (sentivities 64% and 89%, p = 0.02). 
Overall, 
18FDG PET/CT has been reported to 
change therapeutic approach in up to 26% of 
patients with recurrent colorectal cancer (Selzner 
et al. 2004; Votrubova et al. 2006).
Despite the high accuracy, false-positive and 
false-negative ﬁ  ndings may be encountered at 
18FDG PET/CT. Post-surgical and post-radiation 
inﬂ  ammatory tissue take up 
18FDG. For this reason, 
18FDG PET/CT imaging should be delayed until 
2 to 3 months after completion of these treatments. 
Conversely, 
18FDG PET/CT performed within one 
month of chemotherapy may yield false-negative 
results because neoplastic tissue might not be 
metabolically active. 
18FDG PET/CT may not 
detect small lesions (  5 mm) (Von Schulthess 
et al. 2006).
In addition, 
18FDG PET/CT, particularly when 
performed only with unenhanced LD-CT, may nor 
sufﬁ  ce when resection of liver metastases is being 
considered. In these patients, further imaging with 
hepatic MRI of dual-phase contrast-enhanced 
multidetector-CT is usually required in order to 
improve lesion detection and provide adequate 
anatomic information.
To summarize, 
18FDG PET/CT is extremely 
useful in the evalution of patients with suspected 
relapse of colorectal cancer, especially in cases 
with elevated carcinoembryonic antigen (CEA) 
and negative, equivocal or non-speciﬁ  c ﬁ  ndings 
on conventional imaging techniques, and to char-
acterize post-therapy presacral masses. Currently, 
18FDG PET/CT is not indicated for screening or 
primary diagnosis or in patients with known dis-
eminated disease. Promising uses of 
18FDG PET/
CT are monitoring chemo-radiotherapy and 
planning target volume in radiotherapic treatment 
(Ciernik et al. 2005; Pelosi et al. 2007).
Lymphomas
Hodgkin’s lymphoma (HL) and non-Hodgkin’s 
lymphoma (NHL) are lymphoid neoplasias that 
have an elevated overall cure rate with current 
treatment modalities. Accurate staging is crucial 
for and adequate selection of therapy, and imaging 
plays an important role in the assessment of these 
patients. Enhanced CT has been the main modality 
used for staging and follow-up, but it is inaccurate 
for detecting involvement of normal-sized lymph 
nodes, spleen and bone marrow, and to exclude 
disease in post-therapy residual masses or enlarged-
nodes. 
18FDG PET is now widely used for staging 
and restaging of HL and agressive NHL, and has 
superseded gallium-67 scintigraphy as the modal-
ity of choice for metabolic imaging of these 
patients. Despite its high sensitivity and speciﬁ  city, 
18FDG PET has limitations related to the absence 
of anatomic precise localization of lesions, the 
non-speciﬁ  c 
18FDG physiological uptake in some 
organs or in benign lesions, and the variable 
18FDG 
avidity of several histologic types.
Current data in the literature suggest the 
improved performance of 
18FDG PET/CT for stag-
ing and restaging of lymphomas as compared with 
contrast-enhanced CT (Freudenberg et al. 2004; 
Schaefer et al. 2004) and 
18FDG PET alone (Allen-
Auerbach et al. 2004), yielding a sensitivity of 
91%–94% and a speciﬁ  city of 88%–100%. 
18FDG 
PET/CT precisely locates tracer activity to a speciﬁ  c 
organ or node, reducing the false-positive ﬁ  ndings 
on 
18FDG PET standalone scans, and facilitates the 
identiﬁ  cation of sites of extranodal disease (Freud-
enberg et al. 2004; Schaefer et al. 2004; Schöder 
et al. 2004). 
18FDG PET/CT has been reported to 
change the stage in up to 10% and 32% of patients 
as compared with 
18FDG PET and CT respectively, 
and to alter patient management in up to 25% 
(Allen-Auerbach et al. 2004; Freudenberg et al. 
2004; Raanani et al. 2006; Hernández-Maraver 
et al. 2006; Miller et al. 2006).
Probably, the most powerful application of 
18FDG PET/CT in lymphomas is the post-therapy 
assessment, especially in patients with residual 
masses, enabling characterization as either ﬁ  brosis 
or viable lymphoma (Fig. 9). It allows earlier detec-
tion of residual or recurrent disease. In order to 192
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Figure 9. Assessment fo residual mass at completion of initial treatment in lymphoma. 9A: Pretreatment 
18FDG PET/CT study of a 27 year-
old man with DLCB NHL. There is an abdominal mass that exhibits intense 
18FDG uptake, consitent with lymphoma 9B: Postreatment 
18FDG 
PET/CT study shows persistent, though decresed in size abdominal soft-tissue mass, and complete resolution of the abnormal metabolic 
activity. The patient has remained free of relapse.193
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avoid false-positives caused by post-therapy 
inﬂ  ammation, it is recommended to perform 
18FDG 
PET/CT at least 3 weeks after chemotherapy, and 
8–12 weeks after completion of radiation therapy 
(Juweid et al. 2007).
There is also evidence that mid-treatment 
18FDG PET and 
18FDG PET/CT are useful as 
prognostic indicators for disease-free and overall 
survival in HL and aggressive NHL, as early as 
after 1–3 cycles of chemotherapy (Jerusalem et al. 
2000; Kostakoglu et al. 2002; Schot et al. 2003; 
Schaefer et al. 2007). Early identiﬁ  cation of the 
patients who will not be cured with primary che-
motherapy allows a change from a potentially toxic 
unsuccessful therapy to a more effective one. 
However, because of the false-positives that may 
result from post-chemoradiotherapy, and the mor-
bidity and mortality associated with salvage treat-
ments (including stem cell transplant), biopsy of 
the 
18FDG-avid lesions is still needed (Schaefer 
et al. 2007). Other signiﬁ  cant pitfalls regarding 
false-positive FDG uptakes after treatment include: 
opportunistic infections, thymic hyperplasia 
following chemotherapy, and bone marrow 
hyperplasia caused by colony-stimulating factor 
administration.
Thus, 
18FDG PET/CT seems to be valuable to 
taylor therapy by separating subgroups of patients 
with worse prognosis who will beneﬁ  t from dif-
ferent schemes of treatment, such as additional 
radiotherapy to areas of bulky disease or myeloab-
lative chemotherapy followed by stem cell trans-
plantation. Occasionally, 
18FDG PET/CT may 
identify localized recurrence or residual disease 
that could be treated with radiation therapy.
False-negative ﬁ  ndings have been described 
with lesions less than 1 cm, especially in the bases 
of lung, with small lesions in the liver or brain and 
mucosa-associated lymphoid tissue (MALT) NHL, 
because of the high 
18FDG uptake in surrounding 
tissues, and also with low-grade lymphomas show-
ing a low 
18FDG uptake. In this regard, it is impor-
tant to be aware of the histologic type of lymphoma 
when interpreting a 
18FDG PET/CT. Although there 
exists considerable overlap in the intensity of 
18FDG uptake, indolent lymphomas usually show 
lower 
18FDG avidity than aggressive ones (Elstrom 
et al. 2003; Schöder et al. 2005). HL, difuse large 
B cell (DLBCL) NHL, and follicular lymphoma 
are consistently 
18FDG avid. Conversely, periph-
eral T-cell, MALT, and small lymphocytic lym-
phoma exhibit variable, generally low 
18FDG 
avidity, and may not be detectable on 
18FDG PET 
scans. In this setting, the enhanced CT component 
of 
18FDG PET/CT adds valuable information, and 
facilitates detection of low-intensity 
18FDG uptake 
within lymph nodes or other lesions (Allen-
Auerbach et al. 2004). On the other hand, 
18FDG 
PET/CT may be useful in patients with low-grade 
NHL as an indicator of histologic transformation 
into a more aggressive disease (Schöder et al. 
2005). If an unexpected increase in the intensity 
of 
18FDG is detected in sites of disease with previ-
ously documented low uptake, 
18FDG PET/CT may 
direct biopsy to such lesions in order to conﬁ  rm 
transformation into a high-grade NHL.
Finally, the optimal protocol of 
18FDG PET/CT 
for lymphomas is not yet determined. There is 
controversy as to the necessity of performing the 
CT component with intravenous iodinated contrast 
material (Schaefer et al. 2004; Raanani et al. 2006). 
Our own initial results (Rodríguez-Vigil et al. 




PET/CT) and contrast-enhanced full-dose 
18FDG 
PET/CT (FD-
18FDG PET/CT) for lymph node and 
extranodal disease, suggesting that LD-
18FDG 
PET/CT might sufﬁ  ce as the only imaging modal-
ity in most patients with lymphoma, reducing 
contrast toxicity and radiation exposure. FD-
18FDG 
PET/CT could be reserved for selected cases such 
as those with liver or splenic involvement. One 
approach could be to perform FD-
18FDG PET/CT 
at initial staging and, unless the study shows 
18FDG 
PET-negative lymphoma or hepatic or splenic 
involvement, continue performing LD-
18FDG 
PET/CT on follow-up (Rodríguez-Vigil et al. 2006; 
Juweid et al. 2007).
Malignant melanoma
Malignant melanoma has the potential to metasta-
tize anywhere in the body, including unusual sites 
such as myocardium, meninges, and gastrointesti-
nal tract, and shows one of the highest 
18FDG 
uptakes of all tumors. For these reasons, whole-
body
18FDG PET has been proven to be highly 
effective for staging patients with high-risk mela-
nomas (Eigtved et al. 2000; Tyler et al. 2000). 
However, metastases with no or weak 
18FDG PET 
uptake may occur (Aquino et al. 2006). In addition 
the value of 
18FDG PET imaging is limited for the 
depiction of metastases in the brain due to the high 
background activity of surrounding tissue, of small 194
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metastases, particularly in the lung, and of the 
necrotic lymph node metastases. The integrated 
18FDG PET/CT modality avoids some of these 
false-negative ﬁ  ndings at 
18FDG PET. The diag-
nostic accuracy of PET/CT has been shown to be 
signiﬁ  cantly higher than that of PET alone and CT 
alone for M-staging (0.98 vs 0.93 and 0.84 respec-
tively), and signiﬁ  cantly higher than that of CT for 
N-staging (0.98 vs 0.86), leading to a change in 
treatment in 48.4% of patients (Reinhardt et al. 
2006). In a recent prospective study, Strobert et al. 
(Strobert et al. 2007) found that the added CT 
information improved the overall accuracy of 
integrated 
18FDG PET/CT for depiction of mela-
noma metastases as compared with the readout on 
the basis of 
18FDG PET information alone (96% 
vs 91%, p = 0.016). In 13% of patients metastases 
were detected only by using coregistered CT, espe-
cially metastases in the lung with no 
18FDG accu-
mulation.
18FDG PET/CT has become the standard diag-
nostic tool for patients with high-risk melanoma 
(Breslow thickness  1.5 mm or know metastases). 
On the other hand, 
18FDG PET is less useful in 
patients without nodal or distant metastases (stage 
I-II) because of the higher sensitivity of sentinel 
node biopsy for detection of microscopic nodal 
metastases (Havenga et al. 2003).
Head and neck tumors
Conventional imaging of head and neck tumors 
with CT and MRI that rely on morphologic changes 
is limited by their insensitive to detect metastases 
in normal-sized lymph nodes and early recurrences 
due to the post-therapy anatomic distortion and 
persistent contrast enhancement of benign tissue. 
Serial imaging is often needed to conﬁ  rm stability 
of the lesion, suggesting scar or to evidence inter-
val growth, indicating residual or recurrent disease, 
with a considerable delay in diagnosis and treat-
ment. 
18FDG PET has a higher sensitivity than 
MRI/CT, but the poor spatial resolution in this 
complex anatomy of the head and neck, and the 
variable physiologic uptake of 
18FDG in normal 
structures such as muscles, brown fat, salivary 
glands, and the lymphoid tissue in the Waldeyer 
ring reduce its specificity and effectiveness 
(Blodgett et al. 2005; Fukui et al. 2005).
Enhanced 
18FDG PET/CT has been reported to 
be superior to 
18FDG PET or CT alone for the 
evaluation of malignancy in the head and neck, 
with overall sensitivity, speciﬁ  city, and accuracy 
of 98%, 92% and 94%, against 74%, 75% and 74% 
of CT, and 87%, 91% and 90% of 
18FDG PET 
respectively. 
18FDG PET/CT showed an excellent 
negative predictive value (99%) (Branstetter et al. 
2005). In a recent report, 
18FDG PET/CT led to a 
TNM staging alteration in 34%, a change in radio-
therapy planning technique and/or dose in 29%, 
and altered therapy response assessment in 43% 
of patients with squamous cell carcinoma of head 
and neck (Connell et al. 2007).
Indications of 
18FDG PET/CT for head and neck 
cancer include: identiﬁ  cation of unknown primary, 
initial staging for the tumor, nodes, and metastases, 
and detection of residual or recurrent disease after 
therapy (Funki et al. 2005; Hojgaard et al. 2007). 
It is also emerging as the method of choice for 
radiation therapy planning (Hojgaard et al. 2007). 
18FDG PET/CT may be helpful in the search for a 
potential primary head and neck tumor in patients 
presenting with cervical metastatic adenopathies, 
and may direct biopsy in a second endoscopy. It 
has been reported that 
18FDG PET/CT suggests the 
primary site in up to 68% of patients with unknown 
primary tumors (Gutzeit et al. 2005; Nanni et al. 
2005; Wartski et al. 2007). 
18FDG PET/CT allows 
a better depiction of the extent of the primary 
tumor, providing valuable information for the 
surgeon and/or radiotherapist. For regional nodal 
staging the main advantages of integrated 
18FDG 
PET/CT are the ability to detect metastatic inﬁ  ltra-
tion in normal-sized lymph nodes and better 
lymphadenopathy localization. In a recent study 
18FDG PET/CT was superior to 
18FDG PET and 
CT alone for predicting metastatic nodes on a level-
by-level analysis (sensitivity 91.8%, speciﬁ  city 
98.9%, and accuracy 97.1%), and also for the 
pathological nodal classiﬁ  cation (accuracy 85.1%) 
(Jeong et al. 2007). An additional advantage of 
performing whole-body 
18FDG PET/CT is that it 
allows screening for distant metastases and syn-
chronous second primary cancer. Although distant 
metastases are uncommon in head and neck cancers 
it is important to detect them because a large num-
ber of patients will receive loco-regional treatment 
only (surgery and/or radiation therapy). Second 
primary tumors are relatively frequent in this 
population, particularly lung and esophageal car-
cinomas because of the common risk factors for 
these neoplasias (Fukui et al. 2005; von Schulthess 
et al. 2005) (Fig. 10). In patients with early and 
advanced stage primary head and neck squamous 195
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Figure 10. Synchronous lung cancer in a patient undergoing initial staging for laryngeal squamous carcinoma. 10A: axial contrast-enhanced 
CT (A), axial PET (B) and fused axial 
18FDG PET/CT (C) images at the level of vocal cords show a mass with intense 
18FDG uptake in the 
larynx consistent with laryngeal carcinoma. A focus of increased tracer activity is also identiﬁ  ed in the right lung at the coronal PET scan (D). 
10B: axial contrast-enhanced CT (A), PET (B), and fused 
18FDG PET/CT (C) images at the lung bases. A peripheral lung mass abutting the 
pleura with a rim of increased 
18FDG uptake is observed in the right lower lobe.196
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cell carcinoma 
18FDG PET/CT ﬁ  ndings led to a 
change in the treatment plan in 31% of patients, 
mostly by upstaging (Ha et al. 2006). Probably, the 
most important application of 
18FDG PET/CT in 
head and neck cancer is the assessment after treat-
ment. Current data show a better performance of 
18FDG PET/CT than either 
18FDG PET or CT for 
detection of recurrent disease with sensitivities 
around 95%, and speciﬁ  cities of 60% (Zimmer 
et al. 2005; Fakhry et al. 2007). 
18FDG PET/CT 
enables earlier detection of recurrences and with 
greater radiologists conﬁ  dence than with CT alone 
(Fukui et al. 2005).
There are some limitations of 
18FDG PET/CT 
in evaluating head and neck cancers. It is important 
to take into account the interval of time between 
18FDG PET/CT and chemo-radiotherapy, as both, 
false-positive and false-negative ﬁ  ndings have 
been reported when performed within 3 months of 
treatment. The optimal timing for post-therapy 
reevaluation is debatable, but it has been suggested 
that 
18FDG PET/CT be performed at least 8–12 
weeks after initial surgery or chemo-radiotherapy 
in order to obtain a more reliable malignancy sta-
tus evaluation (Hojgaard et al. 2007). The sensitiv-
ity of 
18FDG PET/CT decreases for tumors smaller 
than 1 cm, especially ﬂ  at mucosal lesions or those 
near normal structures displaying physiologically 
high 
18FDG accumulation (brain, tonsils). In addi-
tion, the 
18FDG uptake may be underestimated in 
small lesions owing to partial volume averaging 
with normal tissue and show apparentely benign 
values. On the other hand, some slow-growing 
salivary gland tumors (mucoepidermoid, adenoid 
cystic tumors), and spindle cell neoplasms may 
have a low avidity for 
18FDG and yield false-
negative results. Also lymph nodes with extensive 
necrosis may show low tracer uptake and cause 
false-negative ﬁ  ndings (Fukui et al. 2005).
Other Indications and Other Tracers
18FDG PET/CT is also indicated in the staging and 
restaging of iodine-negative thyroid cancer: dedif-
ferentiated papillary or follicular cancer (neoplas-
tic cells lose their ability to accumulate iodine), 
and advanced Hürtle cell and medullary carcinoma 
(Schmid et al. 2003).
18FDG PET/CT is also a useful imaging modal-
ity in the assessment of response to treatment and 
detection of relapse in other metabolically active 
cancers, such as musculoskeletal sarcomas, 
gastrointestinal stromal tumors and esophageal 
carcinomas. 
18FDG PET/CT has proved useful in 
the detection of metastases that can be unsual in 
appearance or in unexpected locations in patients 
with esophageal carcinoma (Bruzzi et al. 2007). It 
has been reported to be superior to PET or CT alone 
and change patient management in up to 22% by 
detecting nodal and organ metastases (Schöder 
et al. 2004; Weber et al. 2004).
Though well-differentiated hepatocellular car-
cinomas (HCC) do not consistently show increased 
18FDG uptake, 
18FDG PET/CT may be useful in 
patients with poorly differentiated HCC, particu-
larly in depiction of distant metastases of post-
therapy recurrence (Von Schulthess et al. 2006). 
Furthermore, it may have a role in the selection of 
liver transplantation candidates. Yang et al. (Yang 
et al. 2006) have found that 
18FDG PET was a good 
preoperative tool for predicting post-transplantation 
tumor recurrence in these patients.
Preliminary studies also suggest that 
18FDG 
PET/CT may be valuable for ovarian, cervical, and 
endometrial cancer (von Schulthess et al. 2006).
Other PET tracers more tumor-speciﬁ  c than 
18FDG are being explored for certain cancers. 
These new tracers depict amino acid metabolism, 
receptor density, tissue hypoxia, angiogenesis and 
apoptosis, and could prove valuable in tumors with 
low avidity for 
18FDG, such as prostate cancer. 
18F-choline and 
18F-ethyl coline may become use-
ful in prostate carcinoma staging (von Schulthess 
et al. 2006). Amino acids labeled with radionu-
clides such as 
11C-methionine, 
18F-ethyl tyrosine, 
18F-fluoro-alpha-methyl tyrosine (FAMT) and 
18F-thymidine are markers of protein synthesis 
(Oriuchi et al. 2006). They are potentially more 
cancer-speciﬁ  c than 
18FDG as they do not accu-
mulate in inﬂ  ammatory tissue, but are less sensitive 
for tumor staging. FAMT has shown promising 
results in detection of pancreas, liver and brain 
tumors (Inoue et al. 2001) because it does not show 
intense accumulation in these organs. Also, octreo-
tide derivates and 
18F-DOPA are being investigated 
as markers of neuroendocrine tumors (von 
Schulthess et al. 2006).
To summarize, 
18FDG PET/CT has emerged as 
powerful imaging tool in clinical oncology due to 
the synergistic advantages of its components. It 
has become the new standard imaging modality 
for many types of cancer. Despite its beneﬁ  ts, 
18FDG PET/CT has recognized limitations, and 
some clinical questions remain open. Ongoing 197
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research programmes will probably cast light on 
these issues. In addition, the application of new 
PET tracers other than 
18FDG that target speciﬁ  c 
biological characteristic of various cancer cells 
holds promise for further improvements in the 
management of cancer patients.
References
Allen-Auerbach, M., Quon, A., Weber, W.A. et al. 2004. Comparison 
between 2-deoxy-2-(18F)ﬂ  uoro-D-glucose positron emission tomog-
raphy and positron emission tomography/computed tomography 
hardware fusion for staging of patients with lymphoma. Mol. Imag-
ing Biol., 6:411–6.
Antoch, G., Stattaus, J., Nemat, A.T. et al. 2003. Non-small cell lung 
cancer: dual-modality ET/CT in preoperative staging. Radiology, 
229:526–33.
Aquino, S.L., Kuester, L.B., Muse, V.V. et al. 2006. Accuracy of transmis-
sion CT and FDG-PET in the detection of small pulmonary nodules 
with integrated PET/CT. J. Nucl. Med. Mol. Imaging, 33:692–6.
Bar-Shalom, R., Yefremov, N., Guralnik, L. et al. 2003. Clinical performance 
of PET/CT in evaluation of cancer: additional value for diagnostic 
imaging and patient management. J. Nucl. Med., 44:1200–9.
Berger, K.L., Nicholson, S.A., Dehdashti, F. and Siegel, A. 2000. FDG-PET 
evaluation of mucinous neoplasms. Correlation of FDG uptake with 
histopahologic features. Am. J. Roentgenol, 174:1005–8.
Blodgett, T.M., Fukui, M.B., Snyderman, C.H. et al. 2005. Combined PET-
CT in the Head and Neck. Part 1. Physiologic, Altered Physiologic, 
and Artifactual FDG Uptake. RadioGraphics, 25:897–912.
Branstetter, B.F., Blodgett, T.M., Zimmer, L.A. et al. 2005. Head and Neck 
Malignancy: Is PET/CT More Accurate than PET or CT alone? 
Radilogy, 235:580–6.
Bristow, R.E., del Carmen, M.G., Pannu, H.K. et al. 2003. Clinically occult 
recurrent ovarian cancer: patient selection for secondary cytoreduc-
tive surgery using combined PET/CT. Gynec. Oncol., 90:519–28.
Brix, G., Lechel, U., Glatting, G. et al. 2005. Radiation exposure of patients 
undergoing whole-body dual-modality 
18FDG PET/CT examinations. 
J. Nucl. Med., 46:608–13.
Brun, E., Kjellen, E., Tennvall, J. et al. 2002. FDG PET studies during 
treatment: prediction of therapy outcome in head and neck squamous 
cell carcinoma. Head Neck, 24:127–35.
Bruzzi, J.F. and Munden, R.F. 2006. PET/CT imaging of lung cancer. 
J. Thorac. Imaging, 21:123–35.
Bruzzi, J.F., Truong, M.T., Macapinlac, H. et al. 2007. Integrated CT-PET 
Imaging of Esophageal Cancer: Unexpected and Unusual Distribution 
of Distant Organ Metastases. Curr. Probl. Diagn. Radiol., 36:21–9.
Carney, J.P. and Townsend, D.W. 2003. CT-based attenuation correction for 
PET/CT scanners. In: von Schulthess. Ed. Clinical molecular anatomic 
imaging. Philadelphia: Lippincott Williams and Wilkins, 59–63.
Charron, M., Beyer, T., Bohnen, N.N. et al. 2000. Image analysis in patients 
with cancer studied with a combined PET and CT scanner. Clin. Nucl. 
Med., 25:905–10.
Christensen, J.A., Nathan, M.A. and Mullan, B.P. 2006. Characterization 
of the Solitary Pulmonary Nodule: 
18FDG PET Versus Nodule-
Enhancement CT. AJR., 187:1361–7.
Ciernik, I.F., Huser, M., Burger, C. et al. 2005. Automated functional image-
guided radiation treatment planning for rectal cancer. J. Radiat. Oncol. 
Biol. Phys., 62:893–900.
Connell, C.A., Corry, J., Milner, A.D. et al. 2007. Clinical impact of, and 
prognostic stratiﬁ  cation by, F-18 FDG PET/CT in head and neck 
mucosal squamous cell carcinoma. Head Neck Jun 11 (Epub ahead 
of print).
Devaraj, A., Cook, GJR. and Hansell, D.M. 2007. PET/CT in non-small 
cell lung cancer staging-promises and problems. Clin. Radiol., 
62:97–108.
Eigtved, A., Andersson, A.P., Dahlstrom, K. et al. 2000. Use of ﬂ  uorine-
18-ﬂ  uorodeoxyglucose positron emission tomography in the detection  
of silent metastases from malignant melanoma. Eur. J. Nucl. Med., 
27:70–5.
Elaini, A.B., Shetty, S.K., Chapman, V.M. et al. 2007. Improved Detection 
and Characterization of Adrenal Disease with PET-CT. Radiograph-
ics, 27:755–67.
Elstrom, R., Guan, L., Baker, G. et al. 2003. Utility of FDG-PET scanning 
in lymphoma by WHO classiﬁ  cation. Blood, 101:3875–6.
Even-Sapir, E., Parag, Y., Lerman, H. et al. 2004. Detection of recurrence 
in patients with rectal cancer: PET/CT after abdominoperineal or 
anterior resection. Radiology, 232:815–22.
Fakhry, N., Lussato, D., Jacob, T. et al. 2007. Comparison between PET 
and PET/CT in recurrent head and neck cancer and clinical implica-
tions. Eur. Arch. Otorhinolaryngol, 264:531–8.
Freudenberg, L.S., Antoch, G., Schutt, P. et al. 2004. FDG-PET/CT in re-
staging of patients with lymphoma. Eur. J. Nucl. Med. Mol. Imaging, 
31:325–9.
Fukui, M.B., Blodgett, T.D., Snyderman, C.H. et al. 2005. Combined PET-
CT in the Head and Neck. Part 2. Diagnostic Uses and Pitfalls of 
Oncologic Imaging. RadioGraphics, 25:913–30.
Greco, C., Rosenzweig, K., Cascini, G.L. et al. 2007. Current status of 
PET/CT for tumour volume deﬁ  nition in radiotherapy treatment 
planning for non-small cell lung cancer (NSCLC). Lung Cancer, 
57:125–34.
Gutzeit, A., Antoch, G., Kuhl, H. et al. 2005. Unknown primary tumours: 
detection with dual-modality PET/CT—initial experience. Radiology, 
234:227–34.
Ha, P.K., Hdeib, A., Goldenberg, et al. 2006. The role of positron emission 
tomography and computed tomography fusion in the management 
of early-stage and advanced-stage primary head and neck squamous 
cell carcinoma. Arch. Otolaryngol. Head Neck Surg., 132:12–6.
Halpern, B.S., Schiepers, C., Weber, W.A. et al. 2005. Presurgical staging 
of non-small cell lung cancer: positron emission tomography, inte-
grated positron emission tomography/CT, and software image fusion. 
Chest, 128:2289–97.
Hany, T.F., Steinert, H.C., Goerres, G.W. et al. 2002. PET diagnostic accu-
racy: improvement with in-line PET-CT system: initial results. 
Radiology, 225:575–81.
Havenga, K., Cobben, D.C., Oyen, W.J. et al. 2003. Fluorodeoxyglucose-
positron emission tomography and sentinel lymph node biopsy in 
staging primary cutaneous melanoma. Eur. J. Surg. Oncol., 29:662–4.
Hernández-Maraver, D., Hernández-Navarro, F., Gómez-León, N. et al. 
2006. Positron emission tomography/computed tomography: 
diagnostic accuracy in lymphoma. Br. J. Haematol, 135:293–302.
Hojgaard, L. and Specht, L. 2007. PET/CT in head and neck caner. Eur. J. 
Nucle. Med. Mol. Imaging, 34:1329–33.
Huebner, R.H., Park, K.C., Sheperd, J.E. et al. 2000. A meta-analysis of the 
literature for whole-body FDG PET detection of recurrent colorectal 
cancer. J. Nucle. Med., 41:1177–89.
Jeong, H.S., baek, C.H., Son, Y.I. et al. 2007. Use of integrated 
18F-FDG 
PET/CT to improve the accuracy of initial cervical nodal evaluation 
in patients with head and neck squamous cell carcinoma. Head Neck, 
29:203–10.
Jerusalem, G., Beguin, Y., Fasotte, M.F. et al. 2000. Persistent tumor 
18F-FDG uptake after a few cycles of polychemotherapy is predictive 
of treatment failure in non-Hodgkin’s lymphoma. Haematologica, 
85:613–8.
Juweid, M.E., Stroobants, S., Hoekstra, O.S. et al. 2007. Use of Positron 
Emission Tomography for Response Assessment of Lymphoma: 
Consensus of the Imaging Subcommittee of International Harmoni-
zation Project in Lymphoma. J. Clin. Oncol., 25:571–8.
Kapoor, V., McCook, B.M. and Torok, F.S. 2004. An introduction to PET-CT 
imaging. RadioGraphics, 24:523–43.
Keidar, Z., Haim, N., Guralnik, L. et al. 2004. PET/CT using 
18FDG in 
suspected lung cancer recurrence: diagnostic value and impact on 
patient management. J. Nucl. Med., 45:1640–46.198
Pinilla et al
Clinical Medicine: Oncology 2008:2 
Kim, S.H., Allen-Auerbach, M., Goldin, J. et al. 2007. Accuracy of PET/CT 
in Characterization of Solitary Pulmonary Lesions. J. Nucl. Med., 
48:214–20.
Kneifel, S. 2003. Radiation doses and radiation protection. In: von 
Schulthess. Ed. Clinical molecular anatomic imaging. Philapelphia: 
Lippincott Williams and Wilkins, 68–71.
Kostaloglu, L., Coleman, M., Leonard, J.P. et al. 2002. PET predicts prog-
nosis after 1 cycle of chemotherapy in aggressive lymphoma and 
Hodgkin’s disease. J. Nucl. Med., 43:1018–27.
Inoue, T., Koyama, K., Oriuchi, N. et al. 2001. Detection of malignant 
tumors: whole-body PET with ﬂ  uorine 18 alpha-methyl tyrosine 
versus FDG-preliminary study. Radiology, 220:54–62.
Lardinois, D., Weder, W., Hany, T. et al. 2003. Staging of non-small cell 
lung cancer with integrated positron-emission tomography. J. Nucl. 
Med., 348:2500–7.
Metser, U., Miller, E., Lerman, H. et al. 2006. 
18FDG PET/CT in the 
Evaluation of Adrenal Masses. J. Nucl. Med., 47:32–7.
Miller, E., Metser, U., Avrahami, G. et al. 2006. Role of 
18F-FDG PET/CT 
in Staging and Follow-up of Lymphoma in Pediatric and Young Adult 
Patients. J. Comput. Assist. Tomogr., 30:689–94.
Nanni, C., Rubello, D., Castellucci, P. et al. 2005. Role of 
18FDG PET-CT 
imaging for the detection of an unknown primary tumour: preliminary 
results in 21 patients. Eur. J. Nucl. Med. Mol. Imaging, 32:589–92.
Oriuchi, N., Higuchi, T., Ishikita, T. et al. 2006. Present role and future 
prospects of positron emission tomography in clinical oncologyl. 
Cancer Sci., 97:1291–7.
Pelosi, E. and Deandreis, D. 2007. The role of 18F-ﬂ  uoro-deoxy-glucose 
positron emission tomography (FDG-PET) in the management of 
patients with colorectal cancer. Eur. J. Surg. Oncol., 33:1–6.
Pfannenberg, A.C., Aschoff, P., Brechtel, K. et al. 2007. Low dose non-
enhanced CT versus standard dose contrast-enhanced CT in combined 
PET/CT protocols for staging and therapy planning in non-small cell 
lung cancer. Eur. J. Nucl. Med. Mol. Imaging, 34:36–44.
Pieterman, R.M., van Putten, JWG., Meuzelaar, J.J. et al. 2000. Preopera-
tiave staging of non-small cell lung cancer with positron-emission 
tomography. N. Engl. J. Med., 343:254–61.
Pozo-Rodríguez, F., Martín de Nicolás, J.L., Sánchez-Nistal, M.A. et al. 
2005. Accuracy of helical computed tomography and (18F) Fluoro-
deoxyglucose positron emission tomography for identifying lymph 
node mediastinal metastases in potentially resectable non-small-cell 
lung caner. J. Clin. Oncol., 23:8348–56.
Raanani, P., Shasha, Y., Perry, C. et al. 2006. Is CT scan still necessary for 
staging in Hodgkin and non-Hodgkin lymphoma patients in the 
PET/CT era?. Ann. Oncol., 17:117–22.
Reinhardt, M.J., Joe, A.Y., Jaeger, U. et al. 2006. Diagnostic performance 
of whole-body 
18FDG PET/CT imaging for N- and M-staging of 
malignant melanoma: experience with 250 consecutive patients. 
J. Clin. Oncol., 24:1178–87.
Rodríguez-Vigil, B., Gómez-León, N., Pinilla, I. et al. 2006. PET/CT in 
Lymphoma: Prospective Study of Enhanced Full-Dose PET/CT 
Versus Unenhanced Low-Dose PET/CT. J. Nucl. Med., 47:1643–8.
Sachelarie, I., Kerr, K., Ghesani, M. et al. 2005. Integrated PET-CT: 
evidence-based review of oncology indications. Review. Oncology, 
19:481–90.
Schaefer, N.G., Hany, T.F., Taverna, C. et al. 2004. Non-Hodgkin lym-
phoma and Hodgkin disease: coregistered FDG PET and CT at 
staging and restaging—do we need contrast-enhanced CT? Radiol-
ogy, 232:823–9.
Schaefer, O. and Langer, M. 2007. Detection of recurrent rectal cancer with 
CT, MRI and PET/CT. Eur. Radiol., 17:2044–54.
Schmid, D.T. and von Schulthess, G.K. 2003. PET and PET/CT of cancers 
of the thyroid. In: von Schulthess. Ed. Clinical molecular anatomic 
imaging. Philapelphia: Lippincott Williams and Wilkins, 280–90.
Schiepers, C.F., Penninckk, F., De Vadder, N. et al. 1995. Contribution of 
PET in the diagnosis of recurrent colorectal cancer: comparison with 
conventional imaging. Eur. J. Surg. Oncol., 21:517–22.
Schöder, H., Larson, S.M. and Yeung, H. 2004. PET/CT in oncology: inte-
gration into clinical mangement of lymphoma, melanoma, and gas-
trointestinal malignancies. J. Nucl. Med., 45(1 suppl):72S–81S.
Schöder, H., Noy, A., Gönen, M. et al. 2005. Intensity of 
18Fluorodeoxy-
glucose Uptake in Positron Emission Tomography Distinguishes 
Between Indolent and Aggressive Non-Hodgkin’s lymphoma. J. Clin. 
Oncol., 23:4643–51.
Schot, B., van Imhoff, G., Pruim, J. et al. 2003. Predicitive value of early 
18F-ﬂ  uoro-deoxyglucose positron emission tomography in chemo-
sensitive relapsed lymphoma. Br. J. Haematol, 123:282–7.
Schrevens, L., Lornet, N., Dooms, C. et al. 2004. The role of PET scan in 
diagnosis, staging, and management of non-small cell lung cancer. 
Oncologist, 9:633–43.
Selzner, M., Hany, T.F., Wildbrett, P. et al. 2004. Does the novel PET/CT 
imaging modality impact on the treatment of patients with metastatic 
colorectal cancer of the liver? Ann. Surg., 240:1027–34.
Shim, S.S., Lee, K.S., Kim, B.T. et al. 2005. Non-smal cell lung cancer: 
prospective comparison of integrated FDG PET/CT and CT alone 
for preoperative staging. Radiology, 236:1011–19.
Shreve, P.D., Anzai, Y. and Wahl, R. 1999. Pitfalls in oncologic diagnosis 
with FDG PET imaging: physiologic and benign variants. Radio-
Graphics, 19:61–77.
Strobel, K., Dummer, R., Husarik, D.B. et al. 2007. High-risk melanoma: 
accuracy of FDG PET/CT with added CT morphologic information 
for detecction of metastases. Radiology, 244:566–74.
Tyler, D.S., Onaitis, M., Kherani, A. et al. 2000. Positron emission tomog-
raphy scanning in malignant melanoma: clinical utility in patients 
with stage III disease. Cancer, 89:1019–25.
Van Baardwijk, A., Baumert, B.G., Bosmans, G. et al. 2006. The current 
status of FDG-PET in tumour volume deﬁ  nition in radiotherapy 
treatment planning. Cancer Treat. Rev., 32:245–60.
Von Schulthess, G.K., Steinert, H.C. and Hany, T.F. 2006. Integrated 
PET/CT: current applications and future directions. Radiology, 
238:405–22.
Votrubova, J., Belohlavek, O., Jaruskova, M. et al. 2006. The role of FDG 
PET/CT in the detection of recurrent colorectal cancer. Eur. J. Nucl. 
Med., 33:779–84.
Wartski, M., Stanc, E.L., Gontier, E. et al. 2007. In search of an unknown 
primary tumour presenting with cervical metastases: Performance of 
hybrid FDG-PET-CT. Nucl. Med. Commun., 28:365–71.
Weber, W.A., Petersen, V., Schmidt, B. et al. 2003. Positron emission 
tomography in non-small cell lung cancer: prediction of response to 
chemotherapy by quantitative assessment of glucose use. J. Clin. 
Oncol., 21:2651–7.
Weber, W.A. and Ott, K. 2004. Imaging of esophageal and gastric cancer. 
Semin. Oncol., 31:530–41.
Wong, T.Z., Paulson, E.K., Nelson, R.C. et al. 2007. Practical Approach to 
Diagnostic CT Combined with PET. AJR., 188:622–9.
Yang, S.H., Suh, K.S., Lee, H.W. et al. 2006. The Role of 
18F-FDG-PET 
Imaging for the Selection of Liver Transplantation Candidates Among 
Hepatocellular Carcinoma Patients. Liver Transpl, 12:1655–60.
Zimmer, L.A., Snyderman, C., Fukui, M.B. et al. 2005. The use of combined 
PET/CT for localizing recurrent head and neck cancer: The Pittsburg 
experience. Ear Nose Throat J., 84:104, 106, 108–10.